Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Literature DB >> 20882131

Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Abstract

The discovery of androgen deprivation therapy (ADT) has been one of the most important advances in the treatment of prostate cancer. Here, the indications for the use of ADT are reviewed, together with the data supporting each indication. The settings for ADT use include cytoreduction; combined ADT and radiotherapy; pathologic node-positive disease; and recurrent, metastatic, or progressive prostate cancer.

Entities: Chemical Disease

Keywords: Androgen antagonists; combined-modality therapy; disease progression; hormonal anti-neoplastic agents; orchiectomy; prostatectomy; prostatic neoplasms; radiotherapy

Year: 2010 PMID： 20882131 PMCID： PMC2935708 DOI： 10.3747/co.v17i0.698

Source DB: PubMed Journal: Curr Oncol ISSN： 1198-0052 Impact factor: 3.677

49 in total

1. Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.

Authors: D Andrew Loblaw; Tom Pickles; Patrick C Cheung; Himu Lukka; Sergio Faria; Laurence Klotz
Journal: Can Urol Assoc J Date: 2009-12 Impact factor: 1.862

2. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation.

Authors: J D Forman; R Kumar; G Haas; J Montie; A T Porter; C F Mesina
Journal: Cancer Invest Date: 1995 Impact factor: 2.176

3. Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.

Authors:
Journal: Oncologist Date: 1997

4. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Authors: Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi
Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544

5. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.

Authors: Urs E Studer; Dieter Hauri; Silvia Hanselmann; Dominique Chollet; Hans-Jürg Leisinger; Thomas Gasser; Edgar Senn; Felix B Trinkler; Reto M Tscholl; George N Thalmann; Daniel Dietrich
Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544

6. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal: Lancet Date: 2002-07-13 Impact factor: 79.321

7. Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide.

Authors: S Pinault; B Têtu; J Gagnon; G Monfette; A Dupont; F Labrie
Journal: Urology Date: 1992-03 Impact factor: 2.649

8. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal: Lancet Date: 2008-12-16 Impact factor: 79.321

9. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.

Authors: Richard Choo; Cyril Danjoux; Sandra Gardner; Gerard Morton; Ewa Szumacher; D Andrew Loblaw; Patrick Cheung; Maria Pearse
Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-04 Impact factor: 7.038

10. Matrine inhibits the proliferation, invasion and migration of castration-resistant prostate cancer cells through regulation of the NF-κB signaling pathway.

Authors: Qi Li; Yiming Lai; Chengbin Wang; Guibin Xu; Zheng He; Xiaohong Shang; Yi Sun; Fan Zhang; Leyuan Liu; Hai Huang
Journal: Oncol Rep Date: 2015-10-21 Impact factor: 3.906

Androgen deprivation therapy for prostate cancer-review of indications in 2010.

1. Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.

2. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation.

3. Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.

4. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

5. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.

6. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

7. Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide.

8. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

9. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.

10. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.

1. Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position.

2. A new dawn in prostate cancer management: Do we have the trials to support it?

3. Imaging of recurrent intramuscular granulomatous masses induced by depot injection of leuprorelin.

Review 4. Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

5. Androgen deprivation therapy and cardiovascular risk.

6. Design of curcumin loaded cellulose nanoparticles for prostate cancer.

7. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer.

8. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.

9. To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy.

10. Matrine inhibits the proliferation, invasion and migration of castration-resistant prostate cancer cells through regulation of the NF-κB signaling pathway.